# Can You Advertise Hormone Therapy (HRT and BHRT) on Google Ads?

Reviewed October 8, 2026 · By Michael Borgia, MedScale Health

## Short answer

As of October 2026, yes, under the split that applies to every prescription drug. In the US, Google lets advertisers use prescription hormone names in ad text and on landing pages without certification, but bidding on keywords that contain them needs certification, and a telemedicine provider needs LegitScript plus Google certification before ads serve. Hormone campaigns count as Health, so no remarketing lists. MedScale Health, a paid acquisition agency for telehealth brands and clinics, builds HRT search on clinic and consultation intent.

## What this means for you

- An in-person clinic can run Google Search ads on hormone therapy, menopause care and consultation intent today, and may name prescription hormones in US ad text and on landing pages without certification.
- Bidding on keywords that contain prescription drug names needs certification, which suits telehealth providers and pharmacies, not in-person-only clinics.
- Telehealth HRT needs LegitScript certification and Google's healthcare certification before its ads serve.
- Plan for Health targeting limits: no Customer Match, remarketing lists or lookalikes.
- Don't present compounded or bioidentical hormones as FDA approved, as safer because they are natural, or as better than approved products.

MedScale Health, a paid acquisition agency for telehealth brands and clinics, runs Google Search for menopause and hormone therapy clinics and telehealth programs. This page covers the Google policies that decide what an HRT or BHRT campaign can say and bid on, and the FDA statements that limit the claims. It makes no claim about what hormone therapy does for any patient. This page is marketing guidance, not medical or legal advice. Platform policies change, so check the sources listed at the end before acting on a specific rule.

## Drug names: ads and landing pages versus keywords

Google's Restricted drug terms policy restricts prescription drug terms in ads, landing pages and keywords. For campaigns targeting Canada, New Zealand or the United States, you may use prescription drug terms for promotional purposes in line with local law. You don't need to be certified to use those terms in ads and landing pages, but you must be certified to keyword-target them, and certification is also required for certain business types, such as online pharmacies, telemedicine providers and pharmaceutical manufacturers.

Google's non-exhaustive list of monitored prescription drugs names hormone brands including Estrace, Estraderm, EstroGel, Premarin, Prometrium, Vagifem and Femring, and testosterone brands such as AndroGel and Depo-Testosterone. The list gives examples, so treat generic hormone names the same way. For an in-person clinic, that means building keywords around hormone therapy, menopause care, the clinic and the consultation rather than drug names. LegitScript lists in-person-only clinics that don't prescribe through telemedicine among businesses generally not eligible for its Healthcare Certification.

## Telehealth HRT needs certification first

Google restricts the promotion of services related to the online prescribing, dispensing and sale of prescription drugs, and names online pharmacies and telemedicine providers among the businesses in scope. Advertisers must be certified by Google to serve ads for prescription drug services. In the US, Google allows telemedicine providers accredited by LegitScript's Healthcare Merchant Certification Program, and the application is made at the child account level with the customer ID and certified domain. Google says it errs on the side of caution with landing pages that appear to facilitate online prescribing, so a menopause page with an online intake that ends in a prescription is in scope even if the ad names no drug.

## Targeting: Health is a sensitive category

Google's Health in personalized advertising policy defines Health to include physical health conditions, products, services or procedures to treat or manage chronic health conditions, and invasive procedures including injections. Plan for hormone therapy ads to be treated as Health. In sensitive categories you can use predefined Google audiences, such as in-market, affinity, demographics and location, but not advertiser-curated audiences: Customer Match, your data segments, audience expansion and lookalike segments.

## Bioidentical and compounded hormone claims

FDA's menopause page says many products marketed as bioidentical hormones are compounded drugs, which are not FDA-approved, and that FDA does not have evidence that compounded bioidentical hormones are safe and effective, or safer or more effective than FDA-approved hormone therapy. It adds that FDA has approved drugs containing hormones identical to those women make naturally, and that there are no FDA-approved drugs containing estriol. FDA's summary of the National Academies review it commissioned notes that these products are often advertised as natural, safer or free of the risks of approved therapies, and that the review found a lack of rigorous evidence of safety and effectiveness.

Those statements set the copy limits. Google's Unapproved substances policy bans non-government-approved products marketed as safe or effective for treating a disease or ailment. FDA's reminders to telehealth companies list calling a compounded drug FDA-approved, or the same as an approved drug, as misleading. LegitScript's transparency standard covers claims of benefits not supported by a regulatory body. "Bioidentical" can describe a product; it can't stand in for "safer". Pellets, creams and injections raise the same two questions: is the product FDA-approved or compounded, and does the ad or keyword name a prescription drug?

## The 2026 label change and what it doesn't say

On February 12, 2026, FDA announced it had approved labeling changes for six menopausal hormone therapy products, removing risk statements about cardiovascular disease, breast cancer and probable dementia from the boxed warning, after starting the process in November 2025. In November 2025 FDA said it was not seeking to remove the boxed warning for endometrial cancer on systemic estrogen-alone products. The change applies to the labels of FDA-approved products. It does not make compounded hormones approved, and it gives an ad no safety claim to borrow: "FDA says hormone therapy is safe" overstates a label change.

## What MedScale does

MedScale Health builds hormone therapy search campaigns on clinic, menopause and consultation keywords, keeps drug names to ad text and landing pages until the account is certified, files LegitScript and Google certification for telehealth programs, and checks bioidentical claims against FDA's statements. MedScale tracks server-side under a BAA with neutral event names, and no names, emails, phone numbers, IP addresses or browser IDs go to any ad platform. No cost per patient is promised. Book the free growth audit at medscale.health/audit for a written plan.

## FAQ

**Can you advertise BHRT on Google?**

Yes, within limits. A clinic can advertise hormone consultations and may name prescription hormones in US ad text, but keyword-targeting drug names needs certification, telehealth prescribing needs LegitScript and Google certification, and FDA has no evidence that compounded bioidenticals are safer.

**Can a menopause telehealth company run Google Ads?**

After certification. Google requires telemedicine providers to be certified by Google to serve ads for prescription drug services, and in the US that requires LegitScript Healthcare Merchant Certification first. The landing page brings a program into scope even if the ad names no drug.

**Can I bid on estradiol keywords on Google?**

Only with certification. In the US, Google allows prescription drug terms in ads and landing pages without certification, but keyword-targeting them requires it. Google's monitored list includes hormone brands such as Estrace and Estraderm.

**Does the 2026 FDA label change let HRT ads make safety claims?**

No. FDA approved labeling changes for specific FDA-approved menopausal hormone products, removing some boxed warning statements. It did not approve compounded hormones, and the endometrial cancer warning on systemic estrogen-alone products was not part of the removal.

## Sources

- [Google Ads policy: Restricted drug terms](https://support.google.com/adspolicy/answer/15595717?hl=en) (checked October 8, 2026)
- [Google Ads policy: Prescription drugs list (non-exhaustive)](https://support.google.com/adspolicy/answer/2430794?hl=en) (checked October 8, 2026)
- [Google Ads policy: Prescription drug services](https://support.google.com/adspolicy/answer/15598647?hl=en) (checked October 8, 2026)
- [Google Ads policy: Healthcare and medicines (United States section)](https://support.google.com/adspolicy/answer/176031?hl=en) (checked October 8, 2026)
- [Google Ads policy: Health in personalized advertising](https://support.google.com/adspolicy/answer/16701855?hl=en) (checked October 8, 2026)
- [Google Ads policy: Unapproved substances](https://support.google.com/adspolicy/answer/15595718?hl=en) (checked October 8, 2026)
- [LegitScript: Healthcare Certification FAQs](https://www.legitscript.com/certification/healthcare-certification/faq/) (checked October 8, 2026)
- [LegitScript: Healthcare Certification (standards and multiple websites)](https://www.legitscript.com/certification/healthcare-certification/) (checked October 8, 2026)
- [FDA Women's Health: Menopause (compounded bioidentical hormones)](https://www.fda.gov/consumers/womens-health-topics/menopause) (checked October 8, 2026)
- [FDA: NASEM study on compounded bioidentical hormone therapy](https://www.fda.gov/drugs/human-drug-compounding/national-academies-science-engineering-and-medicine-nasem-study-clinical-utility-treating-patients) (checked October 8, 2026)
- [FDA: What telehealth companies should know when promoting compounded drugs](https://www.fda.gov/drugs/human-drug-compounding/fda-telehealth-companies-what-know-when-promoting-compounded-drugs) (checked October 8, 2026)
- [FDA news release (Feb 12, 2026): FDA approves labeling changes to menopausal hormone therapy products](https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products) (checked October 8, 2026)
- [FDA news release (Nov 10, 2025): FDA initiates removal of boxed warnings on menopausal hormone therapy](https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy) (checked October 8, 2026)

## Related

- [Can You Advertise Menopause HRT on Meta?](https://medscale.health/answers/can-you-advertise-menopause-hrt-on-meta)
- [Can You Advertise TRT on Google?](https://medscale.health/answers/can-you-advertise-trt-on-google)
- [LegitScript and Google Ads: Which Do You Need, and How Do You Apply?](https://medscale.health/answers/legitscript-vs-google-healthcare-certification)
- [Can You Advertise GLP-1 on Google Ads?](https://medscale.health/answers/google-ads-for-glp-1-telehealth)

Canonical page: https://medscale.health/answers/can-you-advertise-hormone-therapy-on-google